What type of study is this?

September 10, 2025Frontiers in NeurologyOpen Access

Research progress of multimodal biomarkers in the early diagnosis of mild cognitive impairment in Parkinson’s disease

View Full Paper

Ask AI

Bookmark

Multimodal biomarkers improve early diagnosis of mild cognitive impairment, potentially leading to better patient outcomes.
Current clinical diagnosis of mild cognitive impairment shows limitations, impacting timely interventions and disease progression.
The use of neuroimaging, humoral, genetic, and digital biomarkers offers improved sensitivity and reliability for diagnosing mild cognitive impairment.
Early identification strategies can significantly enhance quality of life and reduce the social and medical burden associated with Parkinson's disease.

Authors

HGHuiping GuoNorthwest A&F University XSXiaoming ShenHong Kong Polytechnic University MLMuxuan LyuHong Kong Polytechnic University

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Research highlights early diagnosis of mild cognitive impairment in Parkinson's disease, suggesting multimodal biomarkers can enhance clinical assessments.

Cite This Study

Guo et al. (2025) studied this question.

synapsesocial.com/papers/68c1d98554b1d3bfb60fb2d8 https://doi.org/10.3389/fneur.2025.1652378

View Full Paper

Ask AI

Bookmark

Implication

Research highlights early diagnosis of mild cognitive impairment in Parkinson's disease, suggesting multimodal biomarkers can enhance clinical assessments.

Research progress of multimodal biomarkers in the early diagnosis of mild cognitive impairment in Parkinson’s disease

Key Points

Discussion

Implication

Cite This Study

Research progress of multimodal biomarkers in the early diagnosis of mild cognitive impairment in Parkinson’s disease

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider